Pearce IP BioBlast®: w/e 30 July 2021

by , | Aug 2, 2021

27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar development and manufacturing.

28 Jul 21 | Prestige BioPharma announced that HD201 (proposed trastuzumab biosimilar) demonstrated an equivalent pharmacokinetic and safety profile to reference trastuzumab in a bridging study completed last year.

29 Jul 21 | The FDA announced it has approved the first interchangeable biosimilar insulin product. Semglee® (biosimilar insulin glargine) has been approved as an interchangeable biosimilar to Lantus® and is indicated for adults and paediatric patients with Type 1 diabetes and in adults with Type 2 diabetes.

29 Jul 21 | A new study published in Lancet Oncology reported that pembrolizumab in combination with cetuximab shows promise as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Did you know that you can subscribe to Pearce IP’s updates including our weekly BioBlast® and regular pharma and IP industry news? Click here to receive these updates directly in your inbox.

 

 

 

 

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News

Share This

Share This

Share this post with your friends!